Cargando…

A prospective longitudinal study investigating outcomes including patient-reported outcome measures after surgery for metastatic bone disease: protocol for the BoMA-PRO multi-centre MBD outcomes study

AIMS: Surgery is often indicated in patients with metastatic bone disease (MBD) to improve pain and maximize function. Few studies are available which report on clinically meaningful outcomes such as quality of life, function, and pain relief after surgery for MBD. This is the published protocol for...

Descripción completa

Detalles Bibliográficos
Autores principales: Downie, Samantha, Stillie, Alison, Moran, Matthew, Sudlow, Catherine, Simpson, A. Hamish R. W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The British Editorial Society of Bone & Joint Surgery 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7925207/
https://www.ncbi.nlm.nih.gov/pubmed/33573398
http://dx.doi.org/10.1302/2633-1462.22.BJO-2020-0173.R1
_version_ 1783659233249591296
author Downie, Samantha
Stillie, Alison
Moran, Matthew
Sudlow, Catherine
Simpson, A. Hamish R. W.
author_facet Downie, Samantha
Stillie, Alison
Moran, Matthew
Sudlow, Catherine
Simpson, A. Hamish R. W.
author_sort Downie, Samantha
collection PubMed
description AIMS: Surgery is often indicated in patients with metastatic bone disease (MBD) to improve pain and maximize function. Few studies are available which report on clinically meaningful outcomes such as quality of life, function, and pain relief after surgery for MBD. This is the published protocol for the Bone Metastasis Audit — Patient Reported Outcomes (BoMA-PRO) multicentre MBD study. The primary objective is to ascertain patient-reported quality of life at three to 24 months post-surgery for MBD. METHODS: This will be a prospective, longitudinal study across six UK orthopaedic centres powered to identify the influence of ten patient variables on quality of life at three months after surgery for MBD. Adult patients managed for bone metastases will be screened by their treating consultant and posted out participant materials. If they opt in to participate, they will receive questionnaire packs at regular intervals from three to 24 months post-surgery and their electronic records will be screened until death or five years from recruitment. The primary outcome is quality of life as measured by the European Organisation for Research and the Treatment of Cancer Quality of Life questionnaire (EORTC-QLQ) C30 questionnaire. The protocol has been approved by the Newcastle & North Tyneside 2 Research Ethics Committee (REC ref 19/NE/0303) and the study is funded by the Royal College of Physicians and Surgeons of Glasgow (RCPSG) and the Association for Cancer Surgery (BASO-ACS). DISCUSSION: This will be the first powered study internationally to investigate patient-reported outcomes after orthopaedic treatment for bone metastases. We will assess quality of life, function, and pain relief at three to 24 months post-surgery and identify which patient variables are significantly associated with a good outcome after MBD treatment. Cite this article: Bone Jt Open 2021;2(2):79–85.
format Online
Article
Text
id pubmed-7925207
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher The British Editorial Society of Bone & Joint Surgery
record_format MEDLINE/PubMed
spelling pubmed-79252072021-03-04 A prospective longitudinal study investigating outcomes including patient-reported outcome measures after surgery for metastatic bone disease: protocol for the BoMA-PRO multi-centre MBD outcomes study Downie, Samantha Stillie, Alison Moran, Matthew Sudlow, Catherine Simpson, A. Hamish R. W. Bone Jt Open Oncology AIMS: Surgery is often indicated in patients with metastatic bone disease (MBD) to improve pain and maximize function. Few studies are available which report on clinically meaningful outcomes such as quality of life, function, and pain relief after surgery for MBD. This is the published protocol for the Bone Metastasis Audit — Patient Reported Outcomes (BoMA-PRO) multicentre MBD study. The primary objective is to ascertain patient-reported quality of life at three to 24 months post-surgery for MBD. METHODS: This will be a prospective, longitudinal study across six UK orthopaedic centres powered to identify the influence of ten patient variables on quality of life at three months after surgery for MBD. Adult patients managed for bone metastases will be screened by their treating consultant and posted out participant materials. If they opt in to participate, they will receive questionnaire packs at regular intervals from three to 24 months post-surgery and their electronic records will be screened until death or five years from recruitment. The primary outcome is quality of life as measured by the European Organisation for Research and the Treatment of Cancer Quality of Life questionnaire (EORTC-QLQ) C30 questionnaire. The protocol has been approved by the Newcastle & North Tyneside 2 Research Ethics Committee (REC ref 19/NE/0303) and the study is funded by the Royal College of Physicians and Surgeons of Glasgow (RCPSG) and the Association for Cancer Surgery (BASO-ACS). DISCUSSION: This will be the first powered study internationally to investigate patient-reported outcomes after orthopaedic treatment for bone metastases. We will assess quality of life, function, and pain relief at three to 24 months post-surgery and identify which patient variables are significantly associated with a good outcome after MBD treatment. Cite this article: Bone Jt Open 2021;2(2):79–85. The British Editorial Society of Bone & Joint Surgery 2021-02-12 /pmc/articles/PMC7925207/ /pubmed/33573398 http://dx.doi.org/10.1302/2633-1462.22.BJO-2020-0173.R1 Text en © 2021 Author(s) et al. https://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (CC BY-NC-ND 4.0) licence, which permits the copying and redistribution of the work only, and provided the original author and source are credited. See https://creativecommons.org/licenses/by-nc-nd/4.0/
spellingShingle Oncology
Downie, Samantha
Stillie, Alison
Moran, Matthew
Sudlow, Catherine
Simpson, A. Hamish R. W.
A prospective longitudinal study investigating outcomes including patient-reported outcome measures after surgery for metastatic bone disease: protocol for the BoMA-PRO multi-centre MBD outcomes study
title A prospective longitudinal study investigating outcomes including patient-reported outcome measures after surgery for metastatic bone disease: protocol for the BoMA-PRO multi-centre MBD outcomes study
title_full A prospective longitudinal study investigating outcomes including patient-reported outcome measures after surgery for metastatic bone disease: protocol for the BoMA-PRO multi-centre MBD outcomes study
title_fullStr A prospective longitudinal study investigating outcomes including patient-reported outcome measures after surgery for metastatic bone disease: protocol for the BoMA-PRO multi-centre MBD outcomes study
title_full_unstemmed A prospective longitudinal study investigating outcomes including patient-reported outcome measures after surgery for metastatic bone disease: protocol for the BoMA-PRO multi-centre MBD outcomes study
title_short A prospective longitudinal study investigating outcomes including patient-reported outcome measures after surgery for metastatic bone disease: protocol for the BoMA-PRO multi-centre MBD outcomes study
title_sort prospective longitudinal study investigating outcomes including patient-reported outcome measures after surgery for metastatic bone disease: protocol for the boma-pro multi-centre mbd outcomes study
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7925207/
https://www.ncbi.nlm.nih.gov/pubmed/33573398
http://dx.doi.org/10.1302/2633-1462.22.BJO-2020-0173.R1
work_keys_str_mv AT downiesamantha aprospectivelongitudinalstudyinvestigatingoutcomesincludingpatientreportedoutcomemeasuresaftersurgeryformetastaticbonediseaseprotocolforthebomapromulticentrembdoutcomesstudy
AT stilliealison aprospectivelongitudinalstudyinvestigatingoutcomesincludingpatientreportedoutcomemeasuresaftersurgeryformetastaticbonediseaseprotocolforthebomapromulticentrembdoutcomesstudy
AT moranmatthew aprospectivelongitudinalstudyinvestigatingoutcomesincludingpatientreportedoutcomemeasuresaftersurgeryformetastaticbonediseaseprotocolforthebomapromulticentrembdoutcomesstudy
AT sudlowcatherine aprospectivelongitudinalstudyinvestigatingoutcomesincludingpatientreportedoutcomemeasuresaftersurgeryformetastaticbonediseaseprotocolforthebomapromulticentrembdoutcomesstudy
AT simpsonahamishrw aprospectivelongitudinalstudyinvestigatingoutcomesincludingpatientreportedoutcomemeasuresaftersurgeryformetastaticbonediseaseprotocolforthebomapromulticentrembdoutcomesstudy
AT downiesamantha prospectivelongitudinalstudyinvestigatingoutcomesincludingpatientreportedoutcomemeasuresaftersurgeryformetastaticbonediseaseprotocolforthebomapromulticentrembdoutcomesstudy
AT stilliealison prospectivelongitudinalstudyinvestigatingoutcomesincludingpatientreportedoutcomemeasuresaftersurgeryformetastaticbonediseaseprotocolforthebomapromulticentrembdoutcomesstudy
AT moranmatthew prospectivelongitudinalstudyinvestigatingoutcomesincludingpatientreportedoutcomemeasuresaftersurgeryformetastaticbonediseaseprotocolforthebomapromulticentrembdoutcomesstudy
AT sudlowcatherine prospectivelongitudinalstudyinvestigatingoutcomesincludingpatientreportedoutcomemeasuresaftersurgeryformetastaticbonediseaseprotocolforthebomapromulticentrembdoutcomesstudy
AT simpsonahamishrw prospectivelongitudinalstudyinvestigatingoutcomesincludingpatientreportedoutcomemeasuresaftersurgeryformetastaticbonediseaseprotocolforthebomapromulticentrembdoutcomesstudy